glp-1 safety concerns Do The Benefits of Drugs OutWeigh the Negatives? Mapping the effectiveness and risks
Description
Often considered when patients have plateaued on semaglutide or have specific metabolic indicators
Dermawan D, Purbayanto MAK, An overview of advancements in closed-loop artificial pancreas system
The initial muscle loss seen with GLP-1 RA treatment as well as the ongoing replacement of muscle with fat with treatment cycles involving treatment interruptions can result in unfavorable changes in body composition in patients with obesity that can have profoundly negative repercussions, and can exacerbate obesity-related metabolic and health concerns 14,15,16
In the case of the COMBO group at the beginning, significantly greater resistance to insulin was found, so even discrete changes in weight would be reflected in clinical consequences such as increased frequency of menses and increased progesterone concentrations in ovulation ranges
The trial looked at the safety and effectiveness of tirzepatide in two scenarios: Continuing to take tirzepatide at the maximum tolerated dose (10 or 15 milligrams [mg], depending on the patient) after initial treatment on that dose Lowering the dose to 5 mg after initial treatment to maintain weight loss
This is the best website Ive came across I have lost 30 pounds and Im feeling great and I am ready to lose 30 more
